Nanobiotix S.A.
NBTX
Positions held
Your positionsNBTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Nanobiotix S.A. is positioned in the innovative biotechnology sector, focusing on groundbreaking cancer therapies that leverage nanotechnology, which could revolutionize treatment options for patients.
- The company's target mean price is $53.81, indicating significant upside potential from current levels.
- Despite recent challenges, the stock has a market cap of approximately $1.28 billion, reflecting investor interest in its long-term prospects.
- Nanobiotix S.A. faces a strong sell signal with a score of -16.00, indicating negative market sentiment and potential risks ahead.
- The company reported a revenue growth of -79.2%, highlighting significant financial struggles.
- For 2023, the operating margin was -89.09%, showcasing ongoing operational challenges and inefficiencies.
Fundamentals
| Market cap | $1.17B | Enterprise value | $1.16B | Trailing P/E | — | Forward P/E | -136.94 |
| PEG | — | Price / book | -30.97 | Beta | 0.59 | Dividend yield | 0.00% |
| Revenue growth | -79.2% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -3.2% |
| Profit margin | 0.0% | ROE | — | ROA | -21.3% | Debt / equity | — |
| Current ratio | 1.44 | Free cash flow | -$32.78M | Analyst recommendation | strong_buy | Mean target | $53.92 |
| 52w high | $57.14 | 52w low | $14.78 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $29.6M | -$11.6M | $30.1M | $0.0M | — |
| Op margin | -36.5% | 589.1% | -89.1% | — | — |
| Net income | -$24.0M | -$68.1M | -$39.7M | -$57.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$10.8M | -$68.4M | -$26.8M | -$46.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Nanobiotix Appoints Arnd Christ as CFO
2026-10-01 · NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
2026-09-28 · Can J&J’s Partnership Drive More Upside for Nanobiotix?
2026-09-24 · NANOBIOTIX Provides First Half 2026 Operational and Financial Update
2026-09-22 · Voting Rights and Shares Capital of the Company
2026-09-17 · Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?
2026-09-09 · NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-25 · Voting Rights and Shares Capital of the Company
2026-07-30 · Voting Rights and Shares Capital of the Company
Price (daily)
Full chart · RSI · MACD · patterns